Metabolomic biomarkers from patients with Barth syndrome treated with elamipretide: insights from the TAZPOWER study

Peter J. Oates¹, David A. Brown², Hilary J. Vernon³, Jon A. Gangoiti⁴, and Bruce A. Barshop⁴

¹ Oates Biomedical Consulting, Old Lyme, Connecticut, United States of America
² Stealth BioTherapeutics, Newton, Massachusetts, United States of America
³ Johns Hopkins University, Baltimore, Maryland, United States of America
⁴ University of California San Diego, San Diego, California, United States of America

* Corresponding author: hvernon1@jhmi.edu

Abstract length: 293 words
Text length: 2545 words
No. of references: 52
No. of graphics: 7 (1 table/6 figures)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Summary points

• Exploratory targeted metabolomic analyses of plasma and urine were performed after a double-blind, crossover trial in patients with Barth syndrome receiving elamipretide or placebo for 12 weeks.

• Among 51 “energy-linked” metabolites analyzed in both plasma and urine, prominent changes were observed in metabolites associated with fat metabolism.

• Collectively, plasma medium-chain (C6-C12) acylcarnitines were reduced after 12 weeks of elamipretide treatment in patients with Barth syndrome.

• Urinary acylcarnitine concentrations were also lowered with elamipretide in Barth syndrome patients, most prominently for shorter chain acylcarnitines.

• Elamipretide for 12 weeks also trended to lower 3-methylglutaconate and the ketone body 3-hydroxybutyrate, although these decreases did not reach statistical significance.

• Elamipretide also caused a significant rise in plasma taurine, which has been previously reported to be low in Barth syndrome patients.

• These metabolite changes may be consistent with improved mitochondrial function that precedes the functional benefits observed in patients with Barth syndrome after longer-term therapy.
Abstract

Background

Barth syndrome is an inherited disorder that results from pathogenic mutations in TAZ, the gene responsible for encoding tafazzin, an enzyme that remodels the mitochondrial phospholipid cardiolipin. Barth syndrome is characterized by heart and skeletal muscle myopathy, growth delay, and neutropenia among other features. The TAZPOWER clinical trial investigated the effects of the mitochondria-targeting peptide elamipretide in patients with Barth syndrome.

Methods and findings

TAZPOWER included a randomized, double-blind, crossover study of 12 weeks treatment with elamipretide or placebo in 12 patients with Barth syndrome. A broad spectrum of plasma and urine metabolites were measured using liquid chromatography-tandem mass spectrometry at baseline and after 12 weeks treatment with elamipretide or placebo. Of 51 "energy-linked" metabolites analyzed, we highlight here the effects of elamipretide on the plasma and urinary concentrations of several metabolites previously observed to be abnormal in patients with Barth syndrome. Elamipretide treatment was associated with significantly lowered medium- and short-chain acylcarnitines in plasma and urine, respectively ($p < 0.05$). Acetyl carnitine, 3-hydroxybutyrate, and 3-methylglutaconate trended to decrease after 12 weeks of elamipretide, but these trends did not reach statistical significance. After 12 weeks of treatment, elamipretide had no discernible effect on four amino acids previously characterized as having abnormal concentrations in
patients with Barth syndrome. Lastly, elamipretide caused a significant rise in plasma taurine concentrations, an amino acid which has been observed to be decreased in patients with Barth syndrome.

Conclusions

As evidenced by reduced plasma and urinary content of acylcarnitines and trends for lowered ketone body 3-hydroxybutyrate, fat metabolism in Barth syndrome appears to be modified after 12 weeks of elamipretide treatment. Overall, these data are consistent with the improved mitochondrial function that may precede functional benefits with a longer duration of therapy with elamipretide in patients with Barth syndrome.

Trial registration

ClinicalTrials.gov NCT03098797.
Introduction

First described in 1983 [1], Barth syndrome is a rare and potentially fatal X-linked disease characterized by cardiomyopathy, skeletal muscle weakness, growth delays, and cyclic neutropenia [2]. It is caused by defects in TAZ, a gene whose product, tazzafin, is an enzyme essential for cardiolipin biosynthesis and mitochondrial function (for review see Sabbah [3]). There are no approved therapies for Barth syndrome and a paucity of reliable biomarkers with which to understand disease progression and appropriate treatment in this patient population.

Metabolite measurements in clinical studies have long provided a method for understanding pharmacological mechanisms and for biomarker discovery [4,5]. Recent metabolic and metabolomic studies in Barth syndrome have shown pathological alterations in concentrations of acylcarnitines, products of amino acid catabolism (such as 3-methylglutaconate), the ketone body 3-hydroxybutyrate, certain circulating amino acids, and taurine [6-9]. Whether or not these metabolites can be altered with a putative therapy in Barth syndrome has not been previously explored.

The TAZPOWER study was designed to determine the safety and efficacy of elamipretide in patients with Barth syndrome [10]. Elamipretide is a mitochondria-targeting peptide that interacts with cardiolipin, an essential mitochondrial phospholipid that is synthesized de novo [11,12]. Barth syndrome is caused by pathogenic mutations in the TAZ gene that encodes for tafazzin, a transacylase required for cardiolipin remodeling. Patients with Barth syndrome have increased levels of immature cardiolipin (monolysocardiolipin), decreased remodeled cardiolipin, and resulting mitochondrial
dysfunction [3]. Across numerous pre-clinical models, elamipretide has been shown to improve mitochondrial structure and function in a cardiolipin-dependent manner [13,14], resulting in improved heart and skeletal muscle function.

The present report highlights results from an exploratory analysis of plasma and urinary metabolic data obtained in the double-blind, crossover part of the TAZPOWER study.

Methods

Trial design

The protocol for the TAZPOWER study was approved by the local institutional review board committee [Johns Hopkins University IRB protocol IRB00124162: "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects with Genetically Confirmed Barth Syndrome"]'). The study conformed with the principles of the Declaration of Helsinki and was prospectively registered with clinicaltrials.gov (NCT03098797).

TAZPOWER includes a 28-week, randomized, double-blind, placebo-controlled, crossover assessment of the safety and efficacy of elamipretide in Barth syndrome patients [10]. Twelve male patients ages ≥12 (range, 12-35) years with genetically confirmed Barth syndrome were randomized (1:1) to elamipretide 40 mg once daily or placebo for 12 weeks (period 1) followed by a 4-week washout period, after which patients were crossed over to the alternate treatment for a further 12 weeks (period 2). Patients
were ambulatory but with impaired 6-minute walk test (mean, 395.5 min; range, 313-495 min). Vital signs, including electrocardiogram parameters, were within normal limits. The most commonly reported comorbid medical conditions were cardiomyopathy (67%), neutropenia (58%), and hypotonia (50%). Metabolites were analyzed from plasma and urine samples to identify effects of elamipretide during the placebo and elamipretide arms of the study. The trial design also included an open-label extension treatment period with elamipretide for up to 168 additional weeks.

**Metabolite analyses**

Each patient provided blood and first morning void urine samples on four occasions: pre-drug baseline period 1, end-of-period 1, pre-drug baseline period 2, and end-of-period. Plasma (n = 48) and urine (n = 48) samples were shipped frozen on dry ice to the Biochemical Genetics Laboratory, University of California San Diego for analysis by liquid chromatography-electrospray ionization tandem mass spectrometry per established protocols [15]. Of 378 analytes which were quantified and normalized to internal standards, we focused on 51 metabolites associated with energy metabolism. In addition, values for urine specimens were normalized to urinary creatinine.

One Barth syndrome patient was overtly diabetic throughout the study [mean ± standard deviation blood glucose values 9.1 ± 1.6 mmol/L (n = 10) vs 5.0 ± 0.5 mmol/L (n = 43) in the other 11 patients]. Since chronic hyperglycemia and diabetes are well known to be associated with altered metabolomic profiles and dysfunctional mitochondrial metabolism [16-18], metabolomic data for the patient with diabetes were excluded from
the final exploratory analyses, so the complete dataset sample number per metabolite became 44.

The data reported herein represent highlights with respect to some previously identified metabolites known to be altered in Barth syndrome [6-9]. The $\Delta$ value for a given metabolite was calculated as the 12-week change from baseline in metabolite concentration with elamipretide treatment minus the 12-week change from baseline with placebo treatment.

**Statistical analyses**

The effects of each arm were compared to each other using a paired Student’s $t$-test. Multiple related metabolites were analyzed using a two-way ANOVA, with main factors of metabolite and elamipretide effects, as well as analysis for any interaction among main factors. One metabolite datapoint (in the plasma taurine dataset) was excluded from analysis because it was judged to be an aberrant value that was 8 standard deviations from the mean, resulting in only 10 patients being evaluated for this metabolite. For all other metabolites, 11 patients were evaluated. Data are presented as means ± standard error. Significance was noted using an alpha level of $p < 0.05$. 

145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
Results

Plasma acylcarnitines

Elevated plasma acylcarnitines have been previously reported in Barth syndrome [9] and are commonly observed in other pathologies, in particular cardiomyopathies [19-21]. The changes in circulating levels of medium chain (C6-C12) acylcarnitines identified from TAZPOWER are presented in Fig 1. Patient-specific changes in each of the four acylcarnitines are shown in Fig 1A, with the quantified data plotted in Fig 1B. There was a statistically significant decrease in plasma medium chain acylcarnitines (C6-C12 combined) in the elamipretide-treated arm of the study compared to placebo ($p = 0.007$ for elamipretide effect).

Urinary acylcarnitines

Urinary acylcarnitine levels in urine (normalized to creatinine levels) are presented in Fig 2. There was also a statistically significant reduction in urinary acylcarnitines (C6-C8) with elamipretide compared to placebo ($p = 0.0499$ for elamipretide effect).

Acetylcarnitine

Acetylcarnitine (C2-crn) is typically the most abundant circulating acylcarnitine (present in micromolar concentrations) and has previously been found to be increased in Barth
syndrome [9]. There was a trend for decreased acetylcarnitine levels in both plasma and
urine (normalized to creatinine) following elamipretide treatment, but this decrease did
not reach statistical significance ($p = 0.13$ for elamipretide effect) [Fig 3].

3-Methylglutaconate

Plasma and urinary levels of 3-methylglutaconate are shown in Fig 4. 3-Methylglutaconate has been observed to be increased in most, but not all, individuals with Barth syndrome [2,7,8,22]. In the current study, there was a strong trend for decreased 3-methylglutaconate concentration in both plasma and urine, but this did not reach statistical significance compared to placebo (Fig 4, $p = 0.084$ for elamipretide effect).

3-Hydroxybutyrate

Changes in plasma levels of the ketone body 3-hydroxybutyrate are shown in Fig 5. 3-Hydroxybutyrate (also called β-hydroxybutyrate) has been shown to be robustly increased in Barth syndrome [9], as well as in several heart failure studies [23,24]. In the current study, there was a strong trend for decreased plasma 3-hydroxybutyrate following elamipretide treatment, although this trend did not reach statistical significance compared to placebo ($p = 0.07$ for elamipretide effect).
Plasma amino acids

Differences in plasma concentrations of the amino acids arginine, asparagine, proline, and tyrosine for Barth syndrome patients versus controls have been previously reported [6-9]. In the current study plasma concentrations of proline (125 ± 4 µmol/L), tyrosine (57 ± 3 µmol/L), and arginine (54 ± 4 µmol/L) were within normal ranges previously seen in non-Barth control patients [8]. Baseline plasma concentrations of asparagine were 173 ± 8 µmol/L, a heightened level that corroborates previous findings of elevated plasma asparagine in Barth syndrome [8]. Changes from baseline after 12 weeks of treatment with either placebo or elamipretide for these four metabolites are shown in Table 1. There were no statistically significant changes in the elamipretide arm for any of these four amino acids.

Plasma taurine

Taurine is the most abundant free amino acid in many tissues [25]. An estimated 70% of total body taurine is localized to muscles and plays vital roles in mitochondrial, muscular, and cardiovascular functions [26]. Deficiency of taurine has been linked to impaired mitochondrial energy production and decreased exercise performance and can result in cardiomyopathy [27]. In patients with Barth syndrome, plasma taurine was reported to be 36% lower than age-matched control values (p = 0.07) [9]. Changes in plasma taurine levels in the present study are shown in Fig 6. Compared to placebo, circulating taurine
increased significantly in the elamipretide arm of the study ($p = 0.022$ for elamipretide effect).

**Discussion**

In this study we analyzed energy-related metabolites from plasma and urine samples from patients with Barth syndrome patients treated with elamipretide or placebo for 12 weeks. There are several novel findings from the study. First, groups of plasma and urinary acylcarnitines, commonly elevated as a result of mitochondrial dysfunction across different myopathies, were significantly reduced following elamipretide treatment. Second, 3-methylglutaconate and 3-hydroxybutyrate, metabolites previously reported to be elevated in Barth syndrome, trended to decrease following 12 weeks treatment in the elamipretide arm. Third, circulating levels of taurine, a substance essential for heart, muscle, and mitochondrial function and previously reported to be subnormal in Barth syndrome, was significantly increased after elamipretide treatment. Fourth, several amino acids that have previously been shown to be altered in plasma of Barth syndrome patients were not markedly affected by elamipretide treatment. Overall, these data indicate that elamipretide positively affected mitochondrial bioenergetic function in patients with Barth syndrome after 12 weeks of treatment.
Acylcarnitines

The elevation of plasma acylcarnitines observed in this study is consistent with previous studies in Barth syndrome [9] as well as in other genetic mitochondrial diseases [21,22] and cardiomyopathies [20,28]. In addition, a recent study demonstrated that Barth syndrome patients display a severely blunted ability to upregulate fatty acid oxidation rate in response to increased metabolic demand, and suggested that impaired fat oxidation and oxidative phosphorylation contribute to bioenergetic dysfunction in Barth syndrome [29].

Interestingly, elamipretide treatment was associated with a significant reduction in plasma and urinary acylcarnitines (Figs 1 & 2). This suggests that elamipretide may be improving mitochondrial fatty acid metabolism, as has been observed in numerous cardiac [3,30] and non-cardiac [11] settings, as well as in Barth syndrome model systems [31]. Improved β-oxidation of fatty acids with elamipretide may be attributed in principle to a variety of factors: improved mitochondrial content [32], increased electron flow, and supercomplex function in the mitochondrial inner membrane [33], reduction in ROS formation [11,34], increased transport of fatty acids into the mitochondrial network through cardiolipin-dependent pathways [35-37], or some combination thereof.

Altered cardiac fat catabolism has been found to precede changes in myocardial function [38], and reductions in short- and medium-chain acylcarnitines have correlated with improved cardiac function [39]. These data suggest that the reduction in plasma acylcarnitines by elamipretide may reflect improved mitochondrial metabolism, potentially leading to cardiac remodeling, a supposition supported by observations that longer term
elamipretide treatment was associated with increased stroke volume in Barth syndrome patients [10].

3-Methylglutaconate

Elevated 3-methylglutaconate has been previously observed in Barth syndrome urine and plasma [8,40], although levels of this metabolite have been variable across Barth syndrome patients [2,7,22]. In contrast to the traditional view of 3-methylglutaconate as a product of leucine catabolism, 3-methylglutaconate is currently hypothesized to be a more general marker of inefficient fuel (acetyl-coenzyme A) utilization [41,42]. Accordingly, the trend observed in the present study to lower 3-methylglutaconate with elamipretide (Fig 4) is consistent with improved efficiency of fuel utilization secondary to improved mitochondrial bioenergetic status.

3-Hydroxybutyrate

The ketone body 3-hydroxybutyrate is considered to be an essential carbon source for peripheral organs, particularly during conditions of metabolic stress [43]. This includes heart failure, where myocardial catabolism of fatty acids decreases and increased ketone catabolism are observed [23,24,44]. Concordantly, elevated plasma 3-hydroxybutyrate has been identified as an important metabolite that differentiates Barth syndrome patients from controls [9]. The strong trend for reduction in plasma 3-hydroxybutyrate with elamipretide (Fig 5) may reflect improved mitochondrial catabolism of other carbon
substrates, e.g., fatty acids/acylcarnitines, and a reduced need for ketone-body derived carbon sources to support energetics.

**Plasma amino acids**

Previous studies have identified abnormalities in several circulating amino acids as being potentially characteristic of Barth syndrome. These include increases in plasma asparagine, proline, and tyrosine, as well as a decrease in plasma arginine [6-9]. For reasons that are not entirely clear in the present study the baseline plasma levels of these amino acids were slightly different than previously observed [8,9], although the patients enrolled in this study were approximately 10 years older than previously investigated and were fasted overnight rather than for 3-4 hours. Several patients also received supplemental arginine and citrulline at baseline. As tabulated in Table 1, elamipretide had no significant effect on the amino acids listed.

A marked increase in plasma taurine was observed with elamipretide treatment (Fig 6). Taurine is a non-proteogenic amino acid that is considered essential for bioenergetics and has been shown to be integral for heart and skeletal muscle physiology [26]. Deficiency in taurine is associated with the pathological development of a dilated cardiomyopathy [27], providing rationale for the use of taurine supplementation for patients with congestive heart failure [45]. Plasma taurine was reported to be depressed by roughly 40% in Barth syndrome compared to age-matched controls [9]. Interestingly, treatment with elamipretide significantly elevated plasma taurine concentrations in patients with Barth syndrome (Fig 6). Since taurine is essential for proper mitochondrial
protein synthesis, which supports respiratory chain function, and suppresses excess mitochondrial superoxide production [45], a rise in taurine may be presumably beneficial, although an understanding of the mechanism(s) for this increase will require further investigation.

**Integrated mechanistic insights**

Elamipretide is known to interact with cardiolipin and improve mitochondrial bioenergetics across numerous preclinical models [11]. Cardiolipin is essential for mitochondrial structure and function (for review see Schlame & Greenberg [12]). Protein complexes of the electron transport chain (ETC), fission/fusion machinery, and transporters for proteins/metabolites/nucleotides are all critically dependent on cardiolipin for optimal function [35,46]. The loss of mature cardiolipin in Barth syndrome results in cascades of cellular dysfunction, including loss of energy and redox homeostasis, calcium overload, and cell death (for review see Sabbah [3]). Improved mitochondrial structure [13] and ETC/supercomplex function [33] with elamipretide are also expected to improve the local availability of oxidized FAD and NAD\(^+\) cofactors essential for complete \(\beta\)-oxidation of fats [47,48]. All of these factors may contribute to the decreases in plasma and urine acylcarnitines, as well as the trends for lower acetylcarnitine, 3-methylglutaconate, and 3-hydroxybutyrate observed in this study. Additionally, improved bioenergetic efficiency would reduce the overall need for carbon substrates to support metabolism, which may also contribute to the reductions in various metabolite concentrations observed. These suppositions are in agreement with prior pre-clinical [11,13,49,50] and clinical [51,52] data.
in settings other than Barth syndrome, indicating that elamipretide treatment can bring about a more efficient bioenergetic state.

Conclusions

Overall, these TAZPOWER exploratory metabolomic data indicate that ELAM treatment over a 12-week period in patients with Barth syndrome stabilized or reduced several metabolic indicators of inefficient mitochondrial bioenergetic metabolism. Future work will advance our understanding of acylcarnitines and other metabolites in the setting of Barth syndrome. The observed responses to elamipretide may reflect early signs of improved mitochondrial metabolism and could be consistent with increased cardiac stroke volume in patients with Barth syndrome on longer-duration elamipretide therapy [10].
Acknowledgments

Third-party writing assistance was provided by Peter A. Todd, PhD, and James A. Shiffer, RPh, of Write On Time Medical Communications, LLC, and was funded by Stealth BioTherapeutics Inc. P.J.O. wishes to acknowledge the initiative and steadfast support for this project provided by Dr. Mark J. Bamberger of Stealth BioTherapeutics Inc.

Funding

This work was funded by Stealth BioTherapeutics Inc.

Disclosures

P.J.O., H.J.V., J.A.G., and B.A.B. have served as consultants for Stealth BioTherapeutics Inc. D.A.B. is employed by Stealth BioTherapeutics Inc and receives compensation and equity/shares commensurate with this employment. P.J.O. owns stock and has received share options commensurate with his consulting activities with Stealth BioTherapeutics Inc.
References


networks following cardiac ischemia reperfusion in rats. Commun Biol. 2020
17;3(1):389. doi: 10.1038/s42003-020-1101-3

295(21):7452-69. doi: 10.1074/jbc.RA119.012094


Table 1. Change in plasma amino acid concentrations after 12 weeks treatment with elamipretide or placebo.

<table>
<thead>
<tr>
<th>Amino acid</th>
<th>Mean (SEM) change in concentration (µmol/L) after 12 weeks vs baseline</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>Elamipretide</td>
</tr>
<tr>
<td>Asparagine</td>
<td>–32.7 (14.6)</td>
<td>–2.2 (17.5)</td>
</tr>
<tr>
<td>Proline</td>
<td>–5.1 (6.9)</td>
<td>0.35 (6.7)</td>
</tr>
<tr>
<td>Tyrosine</td>
<td>0.18 (4.3)</td>
<td>–1.3 (3.3)</td>
</tr>
<tr>
<td>Arginine</td>
<td>–3.7 (7.4)</td>
<td>–6.0 (5.5)</td>
</tr>
</tbody>
</table>

Abbreviation: SEM, standard error of the mean.
Figure legends

Fig 1. Plasma medium-chain (C6-C12) acylcarnitines. Change (∆) in medium chain acylcarnitines (6, 8, 10, and 12 carbon; C6-, C8-, C10-, and C12-crn, respectively) after 12 weeks treatment with placebo (PBO) or elamipretide (ELAM): (A) individual plots and (B) mean (± SEM) [n = 11 per group]. *Elamipretide effect (p = 0.007; ANOVA) for all medium chain (C6-C12) acylcarnitines combined.
Fig 2. Urinary acylcarnitines. Mean (± SEM) change (Δ) in acylcarnitines (6 and 8 carbon; C6-, and C8-crn, respectively) after 12 weeks treatment with placebo or elamipretide (n = 11 per group). *Elamipretide effect (p = 0.0499; ANOVA) for C6 and C8 acylcarnitines combined.
Fig 3. Plasma and urinary acetylcarnitine. Mean (± SEM) change (Δ) in plasma and urinary acetylcarnitine (C2-crn) after 12 weeks treatment with placebo or elamipretide (n = 11 per group). Elamipretide effect (p = 0.13; ANOVA). Urinary acetylcarnitine concentrations are adjusted for urinary creatinine concentration.
Fig 4. Plasma and urinary 3-methylglutaconate. Mean (± SEM) change (Δ) in plasma and urinary 3-glutaconate (3-MGC) after 12 weeks treatment with placebo or elamipretide (n = 11 per group). Elamipretide effect (p = 0.084; ANOVA). Urinary 3-methylglutaconate concentrations are adjusted for urinary creatinine concentration.
Fig 5. Plasma 3-hydroxybutyrate. Individual changes (Δ) in plasma 3-hydroxybutyrate (3-HB) concentration after 12 weeks treatment with placebo (PBO) or elamipretide (ELAM) \( [n = 11] \). Elamipretide effect \( (p = 0.07; \text{paired } t\text{-test}) \).
Fig 6. Plasma taurine. Individual changes (Δ) in plasma taurine concentration after 12 weeks treatment with placebo (PBO) or elamipretide (ELAM) [n = 10]. Elamipretide effect (p = 0.022; paired t-test).